Synopsys Undervalued as Market Overlooks AI Revenue Opportunity, Morgan Stanley Says
MT newswire2026/10/20 15:00Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
S-Energy Clarifies Solar Contract Value at KRW 11.04 Billion, Reflecting Its Share
Why Snap Needed an Iron Man Star Before Its $2,195 Glasses Go on Sale

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475
Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.